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Abstract: Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a 20	  
heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to 21	  
chemotherapy. The current standard of care, comprised of surgical resection followed by 22	  
radiation and the chemotherapeutic agent temozolomide, only provides patients with a  23	  
12-14 month survival period post diagnosis. Long-term survival for GBM patients remains 24	  
uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. 25	  
In this review we will describe the mechanisms of resistance, and how they may be 26	  
overcome to improve the survival of GBM patients by implementing novel chemotherapy 27	  
drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis 28	  
and autophagy. 29	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 32	  
Introduction 33	  
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous 34	  
population of cells that are genetically unstable, highly infiltrative, angiogenic, and resistant to 35	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chemotherapy [1].  GBM tumors harbor a series of mutations that provide cells with selective growth 36	  
advantages that promote survival and proliferation in a hostile and hypoxic environment [2].  For 37	  
example, 30-40% of GBM tumors have amplification of the epidermal growth factor receptor (EGFR), 38	  
a tyrosine kinase receptor that activates MAPK and PI3K signaling [3].  In addition, a subset of GBM 39	  
tumors express an EGFRVIII variant in which the extracellular domain of the receptor is lacking, 40	  
resulting in constitutive activation [4].  Tumor suppressor genes, such as p53, p21, p16, and PTEN are 41	  
commonly mutated in GBMs, pointing to the highly unstable nature of the cells [5].  GBM tumors are 42	  
characterized pathologically by the presence of necrotic areas and an aberrant vasculature comprised 43	  
of glomeroid tufts and hyperproliferative, leaky and unorganized blood vessels [1].  44	  
The current standard of care is surgical resection coupled with ionizing radiation (IR) and the 45	  
chemotherapeutic agent temozolomide (Temodar, Temodal, TMZ) [6, 7]. However, this treatment only 46	  
provides GBM patients with a 12-14 month survival period post diagnosis [6, 7]. Despite aggressive 47	  
surgical resection and chemotherapy, almost all GBM patients undergo tumor recurrence. Ninety 48	  
percent of GBM tumors have been shown to recur at the primary site [1]. This can be partly attributed 49	  
to the highly infiltrative nature of the tumor, making complete resection with clean margins nearly 50	  
impossible. In addition, GBM tumors can have extensive regions of hypoxia. This reduction in oxygen 51	  
may limit the efficacy of IR as the generation of DNA-damaging free radicals is decreased [8].  The 52	  
capacity of GBM chemotherapeutic drugs to cross the blood brain barrier (BBB) and enter the tumor 53	  
limits efficacy [9, 10].  The abnormal and leaky tumor vasculature causes high hydrostatic pressure in 54	  
the tumor, thereby, reducing drug delivery to the tumor.  It was proposed that by placing dissolvable 55	  
chemotherapy wafers (Gliadel) in the tumor bed, these obstacles would be diminished or overcome 56	  
[11, 12].  However, even with IR, TMZ and Gliadel combined treatments, Finally, GBMs include a 57	  
population of cells that survive the IR and TMZ treatments and may form a pool of even more 58	  
chemotherapy-resistant cells.  59	  
In the following sections we will address mechanisms of resistance, such as: DNA damage response 60	  
pathways, cancer stem cells, microenvironment-mediated chemotherapy resistance, tumor-derived 61	  
endothelial cells, and autophagy and how these mechanisms can be targeted for therapy. 62	  
2. Glioma Chemotherapy: TMZ and Gliadel 63	  
TMZ is an acid-stable orally administered alkylating drug that crosses the blood brain barrier 64	  
(BBB) [13]. It has excellent uptake and distribution behavior, and there is direct evidence of tumor 65	  
localization [14].  TMZ is a prodrug, and its aqueous chemistry is typical of imidazotetrazine 66	  
compounds (Scheme 1). 67	  
Scheme 1.  Prodrug activation of temozolomide. 68	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 69	  
It undergoes hydrolytic ring opening at neutral or alkaline pH under purely chemical control, and 70	  
the first significant intermediate is the open-chain triazene MTIC [15] (Scheme 1). The activated 71	  
intermediate MTIC is shared with dacarbazine, a prodrug used against malignant melanoma, which in 72	  
contrast, requires hepatic demethylation to release MTIC. From MTIC, methyldiazonium is released, 73	  
which methylates DNA (Scheme 2). The majority (70%) of the methyl groups transferred to DNA 74	  
appear at N7-guanine sites with only about 10% at N3-adenine and 5% at O6-MeG [13, 16]. 75	  
Scheme 2. Biological fate of methyldiazonium ions. 76	  
 77	  
Gliadel is a biodegradable wafer impregnated with carmustine, a small lipophilic alkylating and 78	  
interstrand crosslinking nitrosourea [11, 12].  There are strong parallels between the mechanisms of 79	  
prodrug activation and action of carmustine and TMZ, Scheme 3 [17].  Under physiological 80	  
conditions, spontaneous hydrolysis results in fragmentation of the nitrosourea to realease an 81	  
alkyldiazoinium ion  (in this case chloroethyldiazonium) and an isocyanate [18].  Subsequent reaction 82	  
of the isocyanate with biological macromolecules is not a major contributor to the pharmacology.  83	  
Chloroethyldiazonium in aqueous systems has a complex fate [19, 20], but the therapeutic activity is 84	  
derived from guanine chloroethylation of DNA, in particular at G-O6 positions, and further reaction of 85	  
the monoalkylation adducts to form interstrand crosslinks.  86	  
Gliadel wafers are implanted in the cranial resection cavity prior to IR treatment. The Gliadel 87	  
wafers produce high local concentrations of carmustine directly into the tumor bed after surgery when 88	  
the tumor burden is low [21, 22]. The rationale for this approach is that the resection cavities are 89	  
relatively avascular and Gliadel may target cells missed by systemically administered TMZ or 90	  
carmustine. Furthermore, the wafers release carmustine for several weeks. In contrast, systemically 91	  
administered carmustine persists only for a few hours. Clinical trials demonstrated that Gliadel wafers 92	  
are safe for both newly diagnosed and recurring GBMs [23, 24]. IR plus Gliadel showed greater 93	  
overall survival (OS) than IR alone. However, the combination of IR, TMZ and Gliadel did not show a 94	  
statistically significantly increase in survival over IR and TMZ. As a result, IR and TMZ continue to 95	  
be the standard therapy for GBMs. 96	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Scheme 3.  Mechanism of prodrug activation and action of carmustine. 97	  
 98	  
3. DNA Damage Repair 99	  
3.1 Methyl Guanine Methyl Transferase (MGMT)  100	  
The best-documented mechanism of resistance to TMZ is mediated by the DNA repair protein 101	  
MGMT, which removes methyl groups from O6-MeG lesions that arise from TMZ treatment [25]. 102	  
During the repair process, the modified base is flipped out of the double helical stack so it can enter the 103	  
MGMT active site; its position in the DNA duplex being taken by a lysine residue [26].  In the active 104	  
site, base-catalysis generates a reactive thiolate nucleophile from cysteine 145 (in the human form).  105	  
This cleaves the C-O bond of O6-MeG in a nucleophilic substitution reaction that results in a mixed 106	  
thioether product, leading to the inactivation of the protein (Scheme 4) [27]. MGMT is thus a reagent 107	  
consumed stoichiometrically during the repair reaction, not an enzyme. In the context of TMZ 108	  
antitumor activity, DNA repair by MGMT is the primary mechanism of drug resistance. 109	  
Scheme 4.  Mechanism of action of MGMT and structures of the two clinically tested 110	  
MGMT inactivators. 111	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 112	  
MGMT expression inversely correlates with sensitivity to the alkylating agents TMZ and 113	  
carmustine in glioma cells and glioma stem-like cells [28-30]. Differentiated cells lines with elevated 114	  
levels of MGMT show increased chemoresistance [31, 32]. This dependence has been demonstrated by 115	  
treating glioma, leukemia, ovarian, and breast cell lines with suicide inactivators of MGMT, O6-116	  
Benzylguanine (O6-BG) [33] or 6-[(4-Bromo-2-thienyl) methoxy]-9H-purin-2-amine (PaTrin-2) [34-117	  
36]; MGMT inhibition increased sensitivity to TMZ treatment. 118	  
 Methylation of the MGMT promoter occurs in approximately 45% of newly diagnosed 119	  
glioblastoma patients and is prognostic for response to TMZ treatment [37]. Patients with MGMT 120	  
promoter methylation have increased survival when treated with radiotherapy in combination with 121	  
TMZ, while patients with MGMT-positive tumors do not benefit as greatly from this dual treatment [6, 122	  
28]. Several methods can be employed to determine MGMT status (mRNA levels, protein levels by 123	  
immunohistochemistry (IHC), promoter methylation, and enzyme activity); however, current 124	  
evaluations in the clinic usually only assess MGMT protein expression and promoter methylation. It 125	  
remains unclear which technique has the most prognostic value in the clinical setting. In a new 126	  
retrospective study, Lalezari et al [38] focused on 418 patients with newly diagnosed GBMs, of whom 127	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410 were treated with IR and TMZ. Tumors were analyzed for MGMT protein expression via IHC, 128	  
promoter methylation by methylation-specific PCR (MSP), and individual CpG sites were analyzed by 129	  
bisulfite sequencing (BiSEQ). Low MGMT protein expression (<30% positive cells) and high 130	  
promoter methylation individually correlated with OS and progression-free survival (PFS). MGMT 131	  
MSP correlated with MGMT IHC, and IHC status stratified outcome in the methylated group. This 132	  
data was further validated by BiSEQ analysis of 24 CpG sites within the differentially-methylated 133	  
region 2 (DMR2) of the MGMT promoter. Protein levels inversely correlated with methylation density 134	  
in the DMR2 and showed that hypermethylation (≥3 CpG sites) was correlated with higher OS and 135	  
PFS. Combining analyses of protein expression and promoter methylation offers superior prognosis 136	  
than individual analyses of these factors and was recommended for testing of newly diagnosed GBMs 137	  
[38]. 138	  
 A subpopulation of glioblastoma patients have low MGMT expression with no detectable 139	  
promoter methylation [25], indicating that other molecular mechanisms also regulate MGMT 140	  
expression. Wild type p53, but not mutant p53, downregulates MGMT [39] by sequestering Specific 141	  
protein 1 (Sp1) and preventing its interaction with the MGMT promoter [40]. This is of importance 142	  
because p53 mutations are characteristic of secondary but not de novo GBMs [41]. Since p53 is 143	  
mutated in 11-30 % of de novo GBMs and 60-70% in secondary GBMs [41, 42], other mechanisms 144	  
remain to be elucidated. Recently, Kreth et al [39] focused on the post-transcriptional regulation of 145	  
MGMT and found that MGMT was subject to alternative polyadenylation, giving rise to transcripts 146	  
with varying 3’UTR. The longer 3’UTR was expressed in tumors and absent in normal brain tissue. 147	  
MGMT protein levels were reduced when the elongated transcript was expressed. These results were 148	  
independent of the promoter methylation and were attributed to decreased mRNA stability as a result 149	  
of miRNA regulation. This study provides an explanation for tumors with unmethylated MGMT 150	  
promoter and low MGMT expression and provides further insight into molecular mechanisms that 151	  
regulate MGMT expression. Further studies are needed to evaluate whether the long 3’UTR MGMT 152	  
transcript is a prognostic factor for survival of GBM patients.  153	  
3.2 MGMT Therapeutic Targets 154	  
Inhibition of MGMT in combination with TMZ has been studied as an approach to improve 155	  
treatment of GBMs in the clinic. O6-benzyl guanine (O6-BG) is a small-molecule pseudosubstrate that 156	  
transfers a benzyl group to the MGMT active site cysteine 145 residue, thereby, inactivating MGMT 157	  
and preventing removal of methyl groups from the DNA [26]. Initial phase I clinical trials showed that 158	  
O6-BG effectively inhibits MGMT in GBM tumors, but TMZ therapy in combination with O6-BG 159	  
was limited by myelosuppression [40]. This enhanced toxicity is attributed to O6-BG inhibition of the 160	  
low levels of MGMT in hematopoietic progenitor cells. Studies on MGMT-/- mice, also demonstrated 161	  
that damage to bone marrow was the main source of toxicity. This effect can be averted by 162	  
transplantation of wild-type bone marrow into MGMT-/- mice [41]. A new clinical trial will explore 163	  
the feasibility of infusing hematopoietic progenitors modified to express MGMT via a retroviral vector 164	  
as a way to overcome the limitation of therapy-induced myelosuppression [42].  165	  
 One therapeutic strategy that has been evaluated is the use of increased doses and prolonged 166	  
scheduling of TMZ as a means of depleting MGMT. This approach was shown to decrease MGMT 167	  
activity in peripheral blood mononuclear cells [43]. In addition, a recent phase II study of 58 patients, 168	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with first recurrences, evaluated the efficacy and safety of a 21 days on/7 days off regimen at 75-100 169	  
mg/m2/day. This study only included patients who had previously received TMZ concomitant and 170	  
adjuvant IR, and the study was ended when second progressions occurred. This regimen proved to be 171	  
safe, but none of the patients achieved a complete response. Partial responses for 13% of patients were 172	  
observed as well as 6-month PFS of 11%, showing this regimen had little efficacy for recurrent tumors 173	  
[44].  174	  
 Other approaches utilize RNAi to directly interfere with MGMT protein expression. Using 175	  
MGMT-siRNAs and a novel liposome, LipoTrust EX Oligo for delivery, MGMT was efficiently 176	  
knocked down in glioma cells lines, GBM-stem like cells, and in vivo glioma tumors. In vivo delivery 177	  
was effective whether administered intratumorally in a subcutaneous model or via an osmotic pump in 178	  
an intracranial model. Both in vitro and in vivo, MGMT siRNA enhanced sensitivity to TMZ [45]. 179	  
Another RNAi approach employed a lentiviral-based technology to target MGMT with a small hairpin 180	  
RNA [46]. MGMT was successfully inhibited in TMZ-resistant glioma cultures, enhancing sensitivity 181	  
to TMZ for tumors implanted into the flanks of nude mice. Efficient in vivo transduction of the 182	  
shMGMT vector into GBM xenografts decreased MGMT expression and inhibited tumor growth 183	  
following TMZ treatment. Although this seems a promising therapy, the efficacy and toxicity of these 184	  
viral vectors require further evaluation. 185	  
 Post-translational regulation of MGMT occurs by the 26S proteasome, making this a candidate 186	  
for therapy. Bortezomib (BTZ, PS-341) is a boronic acid dipeptide that inhibits the proteasome and 187	  
markedly reduces levels of MGMT mRNA and protein [47]. Efficacy of combined BTZ and TMZ 188	  
therapy differed between glioma lines and was schedule-dependent. MGMT-negative U87MG cell line 189	  
showed decreased viability and increased apoptosis when TMZ was administered before BTZ, while 190	  
the opposite was true for MGMT-positive T98G cells. This effect was partially mediated through 191	  
MGMT downregulation [47] and speaks to the importance of sequence of therapy in combination 192	  
treatments. Primary glioma stem-like cells were more sensitive to proteasome inhibition by BTZ than 193	  
normal neural stem and progenitor cells due in part to the lower proteasome activity [48], making it an 194	  
attractive therapy to combat recurrence. Phase I studies showed BTZ to be well tolerated with 195	  
thrombocytopenia being the most common toxicity [49, 50]. BTZ is now clinically approved for 196	  
hematopoietic malignancies [50]. 197	  
3.3 Mismatch Repair (MMR) 198	  
The responses to TMZ treatment do not absolutely correlate with MGMT, leading us to believe that 199	  
additional mechanisms are at play. One mechanism thought to mediate resistance is loss of MMR [51]. 200	  
O6-MeG lesions mismatched with thymine bases are recognized by the MMR.  The thymine residue is 201	  
excised; however, in the absence of MGMT, the O6-MeG remains, and, thymine is reinserted opposite 202	  
the O6-MeG. These futile cycles of repair result in activation of ATR and Chk1, generation of double-203	  
strand breaks (DSBs) and eventually apoptotic cell death [13]. Cells with MMR deficiencies do not 204	  
process the mismatch, DNA replication proceeds, and no cell cycle arrest or apoptosis occurs. The 205	  
triggering of cell cycle arrest is FANCD2-dependent, but not ATR-dependent [52]; this response is 206	  
more reminiscent of a DNA crosslinker than a monoalkylator [51]. 207	  
 Many groups have examined the role that MMR plays in mediating responses in the clinic to 208	  
TMZ with conflicting results. In one study, 52 glioma patient samples were assessed for microsatellite 209	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instability (MSI), which is thought to be a result of MMR gene inactivation [53]. Zero patients 210	  
exhibited high MSI, defined as instability in three of five loci analyzed. Direct sequencing of MSH6 211	  
identified mutations, many of which did not hinder generation of wild-type protein. In this study MMR 212	  
deficiency does not appear to contribute to resistance to TMZ therapy [54]. A low MSI rate of 8.5% 213	  
was found in a larger panel of 129 GBM patients and a higher presence of MSI was detected amongst 214	  
the 20 GBMs that had recurred. Consistent with the previous studies, no high MSI was detected, and 215	  
IHC for MMR proteins showed aberrant expression in only one tumor with MSI [53].  A larger scale 216	  
analysis of 624 gliomas further validated the lack of high MSI with an incidence of 0.16% [55].  Paired 217	  
analysis of primary and recurrent tumors, noted no differences in PMS2, MLH1, MSH2, and MSH6 218	  
expression, and promoters of these genes remained unmethylated in both instances [25]. Similarly 219	  
another study saw no apparent correlation between MSH2, MSH6, and PMS2 protein and sensitivity to 220	  
TMZ [28]. Single nucleotide polymorphism (SNPs) analysis of patient samples treated with radiation 221	  
alone or with TMZ showed that 50% harbored MSH6 G268A polymorphisms. However, no OS 222	  
benefit was noted between samples harboring or lacking MSH6 G268A [56].  223	  
In contrast, Rellecke et al [57] observed that all primary de novo glioma cultures in their study had 224	  
detectable transcripts and proteins for MMR genes except for MSH2, which they stratified into high 225	  
and low expression levels. The chemosensitivity of these cells to a panel of chemotherapeutic agents, 226	  
including carmustine, cisplatin, and taxol, was evaluated with 36% of the cultures showing 227	  
insensitivity to all of the agents tested. These cultures were characterized by high expression of MSH2, 228	  
which is thought to be a source of resistance in these cells [57]. Yip et al [58] focused their studies on a 229	  
cohort of The Cancer Genome Atlas (TCGA) recurrent tumors, which had been previously found to 230	  
have MSH6 mutations. Analysis of samples pre and post exposure to alkylating agents showed the 231	  
MSH6 mutations were not present in pre-treatment samples indicative that these mutations arose as a 232	  
result of therapy. This same observation carried over to in vitro work with an A172 glioma line 233	  
selected to be resistant to TMZ. The TMZ resistant line, A172TR3, had reduced sensitivity to TMZ, 234	  
decreased expression of MSH6 and a MSH6 somatic mutation. Similarly, knockdown of MSH6 in the 235	  
glioma U251 line reduced sensitivity to TMZ. All these results were independent of MGMT as the 236	  
glioma lines tested were negative for MGMT as well as the TCGA recurrent samples. However, in 237	  
agreement with previous studies high MSI was not detected [58]. Some of the contradictory reports 238	  
may be attributed to the fact that high levels of MSI have been correlated to deficient MMR and thus 239	  
used as a readout for MMR deficiency, despite reports indicating no correlation between the two [54, 240	  
58]. One hypothesis is that the low levels of MSI observed in some cases might be a result of minor 241	  
MMR players, which are not tested in these analyses [53].  242	  
 Despite the complex interpretation of MSI, we conclude that both the MGMT and MMR 243	  
pathways play major roles in the tumor response to TMZ treatment.  A tumor low in MGMT will 244	  
respond well to initial TMZ therapy but at the cost of accumulated mutations.  Surviving tumor cells 245	  
are likely to have acquired MMR mutations, resulting in acquired tolerance to further TMZ therapy: a 246	  
situation typical of GBMs in the clinic. 247	  
4.0: Targeting a complex vasculature: GBM cancer stem cell, GBM endothelial cells, and 248	  
angiogenic resistant mechanisms.  249	  
4.1: Rationale for targeting GBM vasculature 250	  
Pharmaceuticals 2013, 6 9 
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Judah Folkman proposed in 1971 that inhibition of angiogenesis, the process whereby new blood 251	  
vessels are generated by the proliferation of pre-existing ones, would be an effective anti-tumor 252	  
therapy [59]. Like normal tissues, tumors require a vascular network to deliver nutrients and oxygen, 253	  
and remove harmful metabolic waste products. Tissues exceeding more than 70 µm from blood vessels 254	  
are prone to hypoxia, which if not resolved, leads to apoptosis [8].  As GBM tumors have a highly 255	  
proliferative, albeit abnormal vasculature, it seemed plausible that inhibition of angiogenesis would 256	  
reduce tumor growth and improve the survival of GBM patients. However, despite promising in vitro 257	  
data, the implementations of anti-angiogenic drugs have been challenging as GBM tumors adapt and 258	  
become resistant to therapy. Potential mechanisms will be discussed in further detail below but include 259	  
resistant GBM cancer stem cells (CSCs), differentiation of CSCs into glioblastoma- derived 260	  
endothelial cells (GECs), increased invasion of hypoxic cells, and activation of alternative angiogenic 261	  
pathways. 262	  
4.2 Identification of plastic neural stem cells in the adult brain.  263	  
In 1992, Reynolds and Weiss isolated a population of cells from the striatum of adult mice that 264	  
could be maintained in a non-differentiated self-renewing state but differentiate into astrocytes and 265	  
neurons when cultured on adherent plates [60]. Okano et al expanded this work by finding that adult 266	  
neural stem cells could regenerate and form functional neurons to replace damaged or lost ones [61].  267	  
These findings revolutionized neurobiology suggesting that a population of neural stem cells could be 268	  
maintained throughout adulthood, refuting the long-held 1928 proposal [61, 62] that neurogenesis only 269	  
occurs during embryonic and early post-natal development, and that damaged neuronal cells cannot be 270	  
replaced in the adult brain.  271	  
In 2004 Wurmser et al [63] showed that GFP+ murine neural stem cells cultured with human 272	  
endothelial cells gave rise to GFP+ endothelial cells, suggesting that neural stem cells differentiate into 273	  
endothelial cells. Researchers observed that neural stem cells localize around blood vessels [64-66], 274	  
suggesting an interaction between stem and endothelial cells. This differentiation was not due to cell 275	  
fusion as the GFP+ endothelial cells displayed a normal karyotype but was dependent upon cell-cell 276	  
contact of neural stem cells with endothelial cells. In culture, these GFP+ endothelial cells retained 277	  
endothelial cell markers and formed tubules, the functional capillaries formed by endothelial cells.  278	  
These data confirmed that adult neural stem cells are plastic and provided a novel mechanism of 279	  
angiogenesis in the adult brain.  280	  
The pioneering work of Reynolds and Weiss [60] and Wurmser et al [63] laid the foundation for a) 281	  
the development of the cancer stem cell hypothesis and b) how stem cells can contribute to brain 282	  
vascularization –two important fields that are essential to understanding the development, 283	  
maintenance, and resistance of GBM tumor cells. 284	  
4.3 GBM cancer stem cells differentiate into glioblastoma-derived endothelial cells. 285	  
GBM is characterized by an aberrant vasculature comprised of hyper-proliferative endothelial cells, 286	  
glomeroid tufts, and disorganized blood vessels – phenotypes that are absent in lower grade brain 287	  
tumors [67]. The reason for this characteristically aberrant vasculature in GBMs has remained elusive 288	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for decades; however, recent findings have begun to elucidate explanations for this aberrant 289	  
vasculature. 290	  
Starting in 2010, several groups published findings suggesting that endothelial cells contain the 291	  
same genetic aberrancies found in GBM tumors cells [68-71]. Ricci-Vitiani et al [68] observed p53 292	  
mutated endothelial cells lining the lumen of blood vessels in GBM archived material.  Wang et al [69] 293	  
found endothelial cells with amplified chromosome 7, an amplification characteristic of GBM tumor 294	  
cells that results in over expression of EGFR. These observations led to the hypothesis that these 295	  
mutated endothelial cells are derived from GBM CSCs, consistent with the precedent that neural stem 296	  
cells can differentiate into endothelial cells [63]. To determine if CSCs can differentiate into GECs, 297	  
Wang et al [69] isolated a population of cells from human GBM tumors that co-expressed the stem cell 298	  
marker, CD133+, and the endothelial progenitor marker, CD144+. Culture of these double positive cells 299	  
in endothelial rich media decreased expression of the CD133+/CD144+ markers and increased markers 300	  
for mature, proliferating endothelial cells. Furthermore, the differentiated endothelial cells derived 301	  
from the CSCs showed uptake of acetylated DiI-low density lipoprotein, an assay used to mimic the 302	  
functional capability of endothelial cells to transport fluids, suggesting that GECs are functional. It 303	  
should be noted that not all GECs were functional and a portion of them formed structures reminiscent 304	  
of glomeroid tufts when plated on Matrigel, indicating that GECs may contribute to the abnormal 305	  
vasculature of GBMs.  Furthermore, in vivo lineage tracing of GFP+/CD133+ cells implanted into nude 306	  
mice resulted in GFP+/CD105+ cells negative for murine endothelial markers, indicating that the in 307	  
vivo differentiation of a CSC to a rapidly proliferating GBM endothelial cell is possible. However, a 308	  
recent study reported GBM tumors are comprised of a low percent of tumor-derived endothelial cells 309	  
(TDECs) which were not found to be incorporated in the blood vessel. This group questions the 310	  
clinical relevance of TDECs [72]. 311	  
This exciting discovery led researchers to question whether GECs affect tumor angiogenesis and if 312	  
it is possible to target the pathways that regulate GEC differentiation to reduce tumor vasculature 313	  
development.  Ricci-Vitiani et al [68] determined that suppressing differentiation of GBM 314	  
neurospheres to endothelial cells reduced tumor growth and eliminated vascular glomeruli, suggesting 315	  
that GECs contribute to GBM tumor growth and vasculature development.  Wang et al [69] 316	  
demonstrated that both NOTCH, which is essential for the maintenance of CSCs, and VEGF pathways 317	  
regulate the differentiation of GBM cancer stem cells to GECs. Treatment of CD133+ cells with 318	  
Bevacizumab, a monoclonal antibody against VEGFA, did not block progression of CD133+ cells to 319	  
an early endothelial state (CD133+/CD144+), but did block double positive cells from differentiating 320	  
into CD105+ cells, suggesting that VEGFA is essential for double positive cells to reach a mature, 321	  
rapidly proliferating endothelial state.  Conversely, when CD133+ cells were treated with the small 322	  
molecule NOTCH inhibitor, DAPT, the CD133+ cells were unable to transition into early endothelial 323	  
cells (CD133+/CD144+); however, DAPT treatment did not block the differentiation of double positive 324	  
cells from maturing into CD105+ cells. CD105 is a marker for endothelial progenitor cells and is 325	  
absent from normal adult brain. This suggests that VEGFA is necessary for double positive cells to 326	  
reach a mature endothelial cell state while inhibition of NOTCH signaling blocks cells from 327	  
differentiating into endothelial progenitors.  328	  
In contrast, Soda et al [70] suggest that differentiation of murine CSCs to GECs is regulated by 329	  
hypoxia and is VEGF independent. The group found that only a small population of murine TDECs 330	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express VEGFR2 and, although the cells do secrete VEGF, receptor or pathway inhibition does not 331	  
prevent the formation of tubules in vitro. Most noteworthy was the observation that no significant 332	  
increase in survival resulted when tumor-bearing mice were treated with vehicle versus VEGFR 333	  
inhibitor. Surprisingly, the VEGFR-inhibited mice had a statistically significant increase in TDECs 334	  
versus vehicle treated mice, suggesting that the TDECs are resistant to VEGF inhibition. This could 335	  
explain in part why Bevacizumab has only a transient effect in the clinic. It should be noted that Soda 336	  
et al [70] analyzed TDECs generated by a GFAP-Cre /p53 heterozygous mouse injected with Cre-337	  
dependent lentiviruses bearing oncogenes H-Ras and Akt while the aforementioned groups studied 338	  
GBM endothelial cells isolated from human tumors [68, 69]. It is possible that the discrepancies 339	  
between the groups regarding VEGF dependence is due to differences in the models and markers used 340	  
to analyze GBM CSC to endothelial differentiation.   341	  
A recent study suggests that TDECs may also contribute to IR resistance [73]. When GBM cells 342	  
were differentiated to an endothelial cell-like lineage, these cells had decreased apoptosis but increased 343	  
senescence, indicating that the surviving cells are resistant to treatment.  344	  
Lastly, recent data suggests that GBM stem cells further contribute to tumor vascularization by 345	  
differentiating into pericytes, the cells that wrap around endothelial cells to support and maintain them 346	  
[74, 75]. Reduced pericyte coverage results in a less protected and more exposed blood vessel, 347	  
increasing the sensitivity of tumor ECs to radiation and chemotherapy. It is beneficial for the tumor if 348	  
GBM CSCs differentiate into protective pericytes to decrease sensitivity to chemotherapy. 349	  
The identification of a population of CSCs that differentiate into endothelial cells harboring the 350	  
same genetic aberrancies of GBM tumor cells may not only explain the abnormal vasculature observed 351	  
in GBMs but may also play a role in resistance to anti-angiogenic therapies and IR.  The existence of 352	  
GECs in GBMs may provide a novel therapeutic target in which the inhibition of differentiation may 353	  
reduce tumor burden via decreased tumor angiogenesis. However, the feasibility and success of the 354	  
treatment remains to be seen as GBM patients have a moderate and transient response to anti-355	  
angiogenic inhibitors. The most efficacious treatments may occur as combination therapies in which 356	  
anti-angiogenic inhibitors normalizing the leaky GBM vasculature and generate a small window of 357	  
time for the delivery of chemotherapy agents. 358	  
 359	  
4.43 GBM cancer stem cells and their microenvironment contribute to a chemotherapeutic resistant 360	  
tumor. 361	  
It has been long noted that GBMs are comprised of a heterogeneous population of cells, and it was 362	  
assumed that this heterogeneity arose from differentiated cells acquiring mutations or perhaps mutated 363	  
de-differentiating neural cells. However, several groups in the early 2000s proposed a novel reason not 364	  
only for tumor heterogeneity but also for tumor initiation [76-78]. A small population of cells isolated 365	  
from GBM tumors lacked differentiated neural markers, had the capacity to self-renew, proliferate, 366	  
differentiate, and also gave rise to tumors that could be serially maintained while phenotypically 367	  
mimicking the parental GBM tumor [66]. Researchers suggested that this tumor initiating population 368	  
of cells were comprised of GBM CSCs.  This hypothesis had precedents; it had already been suggested 369	  
that CSCs initiate non-solid tumors, such as leukemias, and also some solid tumors, such as breast and 370	  
colon cancers [79]. Although there has been much debate about which markers can be used to isolate 371	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CSCs [80], and whether non-CSCs also can initiate tumors [81, 82], multiple groups have 372	  
substantiated the cancer-stem-cell hypothesis [83, 84]. A particularly exciting topic for future study is 373	  
how stem cells affect the tumor microenvironment and promote chemotherapeutic resistance.  374	  
In order for a tumor to grow, the vasculature must provide the proliferating tumor cells with 375	  
oxygen, nutrients, and a means to dispose of toxic metabolic wastes [85].  If a tumor cell is more than 376	  
70 µm from a blood vessel, it lacks sufficient oxygen and nutrients, and as a result, experiences a 377	  
hypoxic environment.  To alleviate this hypoxia, cells secrete vascular endothelial growth factor 378	  
(VEGF), an angiogenic factor that promotes the recruitment, migration, proliferation, and eventually 379	  
formation of additional blood vessels. GBMs are characterized by a hyperproliferative vasculature, 380	  
comprised of glomeroid tufts and highly branched but dead-end blood vessels [1]. This aberrant 381	  
vasculature may be due in part to GBM CSCs themselves secreting VEGF and stromal derived factor 1 382	  
(SDF1), thereby, promoting tumor vasculature development [86, 87]. In a rat glioma model, C6 cancer 383	  
stem cells showed increased expression of VEGF and SDF1 versus non-CSCs, suggesting that these 384	  
cells can initiate angiogenesis, the formation of new blood vessel from pre-existing ones and SDF1-385	  
mediated vasculogenesis, the de novo formation of blood vessels, by recruiting endothelial progenitor 386	  
cells to the tumor bed [87]. Tumors initiated by C6 CSCs had increased microvessel density, increased 387	  
proliferation, and more circulating endothelial progenitor cells than non-CSCs, suggesting these cells 388	  
significantly contribute to the development of tumor vasculature [87]. Rats treated with either a 389	  
monoclonal antibody that binds VEGFA or a small molecule inhibitor of SDF1, resulted in C6 tumors 390	  
with reduced vasculature [87]. However, disrupting tumor vasculature with anti-angiogenic inhibitors 391	  
does not result in complete abolition of CSCs in the vascular niche, and a subset of resilient cells can 392	  
form.  393	  
Although not entirely functional, this vasculature provides tumor cells with nutrients and an 394	  
aberrant microvascular niche for GBM CSCs. Calabrese et al [65] found that human GBM CSCs 395	  
(nestin+/CD133+) preferentially associate with endothelial cells in vivo.  This interaction was verified 396	  
in vitro as human GBM CD133+ cells, when cultured with primary human endothelial cells (PHECs), 397	  
line the PHEC tubule structures.  When CD133+ cells and PHECs were cultured in a transwell system, 398	  
the cells grew five times faster over a two-week span than CD133+ cells cultured without PHECs 399	  
indicating that endothelial cells secrete factors for the maintenance and survival of GBM CSCs and 400	  
may be essential for the stem-like state. However, another study suggested that a direct physical 401	  
interaction must occur in order for endothelial cells to maintain the CSC phenotype [88]. Regardless, 402	  
the data indicates that the two cell types influence each other and this interaction is important for the 403	  
maintenance of stem cells. This relationship was further substantiated when tumor cells injected 404	  
intracranially with PHECs formed tumors more rapidly than tumor cells alone, suggesting that PHECs 405	  
promote CD133+ initiated tumor growth [65].  406	  
In addition to maintaining CSCs, the microvasculature may serve as a protective niche for CSCs by 407	  
shielding them from IR and chemotherapeutic agents, such as TMZ. A recent study by Borovski et al 408	  
[73, 88] found that tumor microvascular endothelial cells (tMVECs) isolated from human GBM 409	  
tumors promoted the proliferation of human CD133+ cells when the co-cultures were exposed to IR. 410	  
Furthermore, tMVECs significantly increased the number of CD133+ cells after IR, suggesting they 411	  
not only promote proliferation but also maintain the CSC population after therapy. In addition to 412	  
protecting CD133+ cells from IR, tMVECs also promoted the proliferation of TMZ-sensitive GBM 413	  
Pharmaceuticals 2013, 6 13 
 
	   13	  
cultures, indicating that tMVECs protect CD133+ cells from chemotherapy.  When co-cultured cells 414	  
(CD133+with tMVECs) were treated with both IR and TMZ, CD133+ cells showed increased 415	  
proliferation, indicating resistance to the standard of care. Different primary GBM lines exhibited 416	  
different levels of “tMVEC protection,” with varying degrees of re-entry into cell cycle and 417	  
proliferation. Borovski et al [73, 88] found that when tMVECs were treated with IR, a small 418	  
percentage of cells underwent apoptosis; however, the majority of the cells survived and entered a G2 419	  
arrest. The IR-treated cells entered a protective but metabolically active senescent state capable of 420	  
promoting proliferation and maintenance of CD133+ cells. Chemotherapeutic resistant tMVECs were 421	  
shown to be clinically relevant as post mortem biopsies of GBM patients revealed senescent tumor 422	  
endothelial cells [73]. These data suggests that tMVECs are inherently resistant to IR-mediated 423	  
apoptosis and create a protective niche for CSCs. Although the mechanism of this tMVEC-induced 424	  
protection has not been elucidated, Borovski et al [73, 88] suggested that tMVECs may regulate 425	  
MGMT expression in tumor cells, and increase the response of DNA repair pathways, as well as 426	  
physically shielding the cancer stem cells from chemotherapy.  427	  
Additional resistance of GBM CSCs to chemotherapy may be gained by increased activation of 428	  
DNA cell cycle checkpoints and repair pathways in CD133+ cells. Bao et al [89] found that IR 429	  
increases the percentage of CD133+ cells, and that IR-treated CD133+ cells have a four to five fold 430	  
reduction in early apoptosis versus IR-treated CD133- cells. Furthermore, Bao et al [89] observed that 431	  
IR CD133+ cells are capable of generating tumors when intracranially implanted into mice, suggesting 432	  
that CSCs are resistant to IR and capable of re-populating the tumor after chemotherapy. Enhanced 433	  
resistance of CD133+ cells may be due to increased activation of DNA damage checkpoint proteins, 434	  
such as ataxia-telangiectasia (ATM) and Chk1 and 2.  Activation of these checkpoints results in cell 435	  
cycle arrest, allowing the CSCs time to repair IR initiated DNA damage. Once the repair is complete, 436	  
the cell can re-enter the cell cycle and initiate secondary tumors. This was substantiated when Bao et al 437	  
[89] found that IR CD133+ cells can form secondary tumors at similar rates of non-IR-treated CD133+ 438	  
cells, suggesting that IR-treated CD133+ cells serve as a source for tumor recurrence. CD133+ resistant 439	  
cells can be sensitized to IR in vitro if treated with checkpoint kinase inhibitors, presenting a potential 440	  
therapeutic target. However, although inhibition of Chk1 or Chk2 is feasible, the clinical application 441	  
may be limited as non-cancer cells also rely on these pathways to repair DNA damage.   442	  
A study by Facchino et al [90] noted the role of increased DNA damage response pathways in 443	  
mediating CSC IR resistance. It was found that BMI1, a member of the polycomb group that represses 444	  
gene expression, is enriched in CD133+ GBM CSCs, possibly increasing recognition and repair of IR 445	  
induced DSBs. Partial knockdown of BMI1 delayed repair of DSBs, which resulted in a S phase block 446	  
as well as increased cell death in IR-treated CD133+ cells, suggesting that BMI1 may play a role in 447	  
promoting CD133+ radiation-resistance. In addition to increasing cell-cycle checkpoints, GBM cancer 448	  
cells may also acquire resistance to IR through the NOTCH pathway. Although the role of NOTCH in 449	  
maintaining neural stem cell self-renewal and inhibiting neural stem cell differentiation has been well-450	  
established, it was not until recently that Wang et al [91] suggested an additional role for this key 451	  
developmental pathway. Analysis of primary human GBM tumors suggests that the NOTCH1 receptor 452	  
and the NOTCH1 intracellular domain (NICD), which translocates to the nucleus and drives gene 453	  
expression, are over-expressed. When CD133+ cells isolated from human GBM tumors are IR treated, 454	  
NOTCH transcription and NOTCH target gene expression is increased. Knockdown of the NOTCH1 455	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receptor in GBM cell lines decreases proliferation and inhibition of NICD in IR CD133+ cells 456	  
significantly decreases clonogenicity, while increasing apoptosis, suggesting that NOTCH protects 457	  
CD133+ cells from IR [92]. CD133+ cells engineered to constitutively express NICD2 show increased 458	  
phosphorylation of AKT, a player in the PI3K pathway that promotes cell survival, and decreased 459	  
apoptosis and increased clonogenicity in response to IR. This finding corroborates a previous study 460	  
that GBM tumor cells require AKT activation to survive [93].  Interestingly, neither decreased 461	  
clonogencity nor increased apoptosis was observed in CD133- cells treated with a NOTCH inhibitor 462	  
and then irradiated, suggesting that NOTCH may preferentially protect CD133+ cells [91]. This may 463	  
occur because CD133- cells are more differentiated and do not rely on NOTCH to maintain stem cell-464	  
like behavior.  465	  
Furthermore, therapies, such as IR and TMZ, primarily induce apoptosis in rapidly proliferating 466	  
cells; however, Chen et al [94] suggest that CSCs are relatively quiescent.  Using a conditional mouse 467	  
model in which CSCs are GFP+, Chen et al [94] found that after treatment with TMZ, it is the CSC 468	  
GFP+ cells that give to secondary tumor formation, suggesting that CSCs are resistant to current 469	  
chemotherapeutics not only by up-regulating genes that promote survival, but also by their inherently 470	  
slow cycling nature.  471	  
 In summary, GBM CSCs reside in microvascular niches that promote stem cell maintenance and 472	  
protect the population from chemotherapy. CSCs promote vasculogenesis as well as angiogenesis, can 473	  
become resistant to chemotherapy by up-regulating cell cycle checkpoints and survival pathways, and 474	  
may mediate tumor recurrence. In addition, recent data suggest that CSCs can differentiate into 475	  
TDECtumor endothelial cells, providing GBMs with an inherent source of tumor vasculature.   476	  
4.4 GBM cancer stem cells differentiate into glioblastoma-derived endothelial cells. 477	  
GBM is characterized by an aberrant vasculature comprised of hyper-proliferative endothelial cells, 478	  
glomeroid tufts, and disorganized blood vessels – phenotypes that are absent in lower grade brain 479	  
tumors [91]. The reason for this characteristically aberrant vasculature in GBMs has remained elusive 480	  
for decades; however, recent findings have begun to elucidate explanations for this aberrant 481	  
vasculature. 482	  
Starting in 2010, several groups published findings suggesting that endothelial cells contain the 483	  
same genetic aberrancies found in GBM tumors cells [92-95]. Ricci-Vitiani et al [92] observed p53 484	  
mutated endothelial cells lining the lumen of blood vessels in GBM archived material.  Wang et al [93] 485	  
found endothelial cells with amplified chromosome 7, an amplification characteristic of GBM tumor 486	  
cells that results in over expression of EGFR. These observations led to the hypothesis that these 487	  
mutated endothelial cells are derived from GBM CSCs, consistent with the precedent that neural stem 488	  
cells can differentiate into endothelial cells [67]. To determine if CSCs can differentiate into 489	  
glioblastoma-derived endothelial cells (GECs), Wang et al [93] isolated a population of cells from 490	  
human GBM tumors that co-expressed the stem cell marker, CD133+, and the endothelial progenitor 491	  
marker, CD144+. Culture of these double positive cells in endothelial rich media decreased expression 492	  
of the CD133+/CD144+ markers and increased markers for mature, proliferating endothelial cells. 493	  
Furthermore, the differentiated endothelial cells derived from the CSCs showed uptake of acetylated 494	  
DiI-low density lipoprotein, an assay used to mimic the functional capability of endothelial cells to 495	  
transport fluids, suggesting that GECs are functional. It should be noted that not all GECs were 496	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functional and a portion of them formed structures reminiscent of glomeroid tufts when plated on 497	  
Matrigel, indicating that GECs may contribute to the abnormal vasculature of GBMs.  Furthermore, in 498	  
vivo lineage tracing of GFP+/CD133+ cells implanted into nude mice resulted in GFP+/CD105+ cells 499	  
negative for murine endothelial markers, indicating that the in vivo differentiation of a CSC to a 500	  
rapidly proliferating GBM endothelial cell is possible. However, a recent study reported GBM tumors 501	  
are comprised of a low percent of TDECs which were not found to be incorporated in the blood vessel. 502	  
This group questions the clinical relevance of TDECs [96]. 503	  
This exciting discovery led researchers to question whether GECs affect tumor angiogenesis and if 504	  
it is possible to target the pathways that regulate GEC differentiation to reduce tumor vasculature 505	  
development.  Ricci-Vitiani et al [92] determined that suppressing differentiation of GBM 506	  
neurospheres to endothelial cells reduced tumor growth and eliminated vascular glomeruli, suggesting 507	  
that GECs contribute to GBM tumor growth and vasculature development.  Wang et al [93] 508	  
demonstrated that both NOTCH, which is essential for the maintenance of CSCs, and VEGF pathways 509	  
regulate the differentiation of GBM cancer stem cells to GECs. Treatment of CD133+ cells with 510	  
Bevacizumab, a monoclonal antibody against VEGFA, did not block progression of CD133+ cells to 511	  
an early endothelial state (CD133+/CD144+), but did block double positive cells from differentiating 512	  
into CD105+ cells, suggesting that VEGFA is essential for double positive cells to reach a mature, 513	  
rapidly proliferating endothelial state.  Conversely, when CD133+ cells were treated with the small 514	  
molecule NOTCH inhibitor, DAPT, the CD133+ cells were unable to transition into early endothelial 515	  
cells (CD133+/CD144+); however, DAPT treatment did not block the differentiation of double positive 516	  
cells from maturing into CD105+ cells. CD105 is a marker for endothelial progenitor cells and is 517	  
absent from normal adult brain. This suggests that VEGFA is necessary for double positive cells to 518	  
reach a mature endothelial cell state while inhibition of NOTCH signaling blocks cells from 519	  
differentiating into endothelial progenitors.  520	  
In contrast, Soda et al [94] suggest that differentiation of murine CSCs to GECs is regulated by 521	  
hypoxia and is VEGF independent. The group found that only a small population of murine tumor-522	  
derived endothelial cells (TDECs) express VEGFR2 and, although the cells do secrete VEGF, receptor 523	  
or pathway inhibition does not prevent the formation of tubules in vitro. Most noteworthy was the 524	  
observation that no significant increase in survival resulted when tumor-bearing mice were treated 525	  
with vehicle versus VEGFR inhibitor. Surprisingly, the VEGFR-inhibited mice had a statistically 526	  
significant increase in TDECs versus vehicle treated mice, suggesting that the TDECs are resistant to 527	  
VEGF inhibition. This could explain in part why Bevacizumab has only a transient effect in the clinic. 528	  
It should be noted that Soda et al [94] analyzed TDECs generated by a GFAP-Cre /p53 heterozygous 529	  
mouse injected with Cre-dependent lentiviruses bearing oncogenes H-Ras and Akt while the 530	  
aforementioned groups studied GBM endothelial cells isolated from human tumors [92, 93]. It is 531	  
possible that the discrepancies between the groups regarding VEGF dependence is due to differences 532	  
in the models and markers used to analyze GBM CSC to endothelial differentiation.   533	  
A recent study suggests that TDECs may also contribute to IR resistance [84]. When GBM cells 534	  
were differentiated to an endothelial cell-like lineage, these cells had decreased apoptosis but increased 535	  
senescence, indicating that the surviving cells are resistant to treatment.  536	  
Lastly, recent data suggests that GBM stem cells further contribute to tumor vascularization by 537	  
differentiating into pericytes, the cells that wrap around endothelial cells to support and maintain them 538	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[97, 98]. Reduced pericyte coverage results in a less protected and more exposed blood vessel, 539	  
increasing the sensitivity of tumor ECs to radiation and chemotherapy. It is beneficial for the tumor if 540	  
GBM CSCs differentiate into protective pericytes to decrease sensitivity to chemotherapy. 541	  
The identification of a population of CSCs that differentiate into endothelial cells harboring the 542	  
same genetic aberrancies of GBM tumor cells may not only explain the abnormal vasculature observed 543	  
in GBMs but may also play a role in resistance to anti-angiogenic therapies and IR.  The existence of 544	  
GECs in GBMs may provide a novel therapeutic target in which the inhibition of differentiation may 545	  
reduce tumor burden via decreased tumor angiogenesis. However, the feasibility and success of the 546	  
treatment remains to be seen as GBM patients have a moderate and transient response to anti-547	  
angiogenic inhibitors. The most efficacious treatments may occur as combination therapies in which 548	  
anti-angiogenic inhibitors normalizing the leaky GBM vasculature and generate a small window of 549	  
time for the delivery of chemotherapy agents. 550	  
4.5 Bevacizumab: a story of success and failure. 551	  
Glioblastoma tumors are characterized by increased VEGF expression as tumor cells secrete this 552	  
key angiogenic factor [86, 87]. Over-expression of VEGFA activates the VEGFR pathway, promoting 553	  
the proliferation, migration, and survival of endothelial cells, resulting in the formation of tumor blood 554	  
vessels. As previously mentioned, tumor angiogenesis is further aided by CSCs differentiating into 555	  
GECs [68-71]. This creates an aberrant vasculature niche that provides tumor cells with the ability to 556	  
survive in an otherwise hypoxic and hostile environment.  Researchers are currently pursuing 557	  
compounds that normalize tumor vasculature to disrupt tumor growth and enhance drug delivery [95].  558	  
The FDA approved the first human monoclonal antibody against VEGFA, Bevacizumab, as a 559	  
second-line treatment for patients with recurrent GBMs [10, 67, 96].  The rationale is that antibody-560	  
bound VEGF is unable to interact and activate the VEGFR 1 and 2 pathways, resulting in decreased 561	  
tumor vasculature formation [10, 97]. Bevacizumab treatment was proposed to decrease angiogenesis, 562	  
edema, and tumor burden in GBM patients [98].  A phase II study found that recurrent GBM patients 563	  
experienced an increased six-month progression-free survival from 9-15% to 25% when treated with 564	  
Bevacizumab (15 mg/kg, every three weeks) and had an overall six-month survival of 54% [97].  A 565	  
second clinical trial suggested that if recurrent GBM patients are treated with Bevacizumab at a lower 566	  
dose but at higher frequency (10 mg/kg, every 2 weeks), the estimated six-month PFS can be increased 567	  
from 25% to 42.6% [67, 97].  Second time relapsed GBM patients had a decreased six-month PFS 568	  
when treated with Bevacizumab (27.8% versus 42.6%), suggesting that GBM tumors cells become 569	  
resistant to the antibody and activate alternative angiogenic pathways that are VEGF independent [10].  570	  
Analysis of GBM tumor tissues suggests that increased ligand to receptor ratio of VEGFA to VEGFR2 571	  
correlates negatively with survival; however, this correlation was not statistically significant [97]. As 572	  
the study was comprised of a small number of patients, the results need to be verified in a larger 573	  
patient cohort.  574	  
Researchers have proposed using Bevacizumab in combination with known chemotherapeutics [10, 575	  
67, 99]. It was suggested that Bevacizumab temporarily normalizes the hyper-proliferative and leaky 576	  
vasculature of GBM tumors, thereby, enhancing delivery of secondary chemotherapeutic drugs. The 577	  
combination of Bevacizumab with Irinotecan, a topoisomerase I inhibitor, was suggested as a potential 578	  
treatment for recurrent GBM patients for three reasons [10]. First, the combination of Bevacizumab 579	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with Irinotecan is efficacious in other aggressive solid tumors; for example, Bevacizumab plus 580	  
Irinotecan increased the OS of metastatic colorectal cancer patients versus single agent or placebo. 581	  
Second, Irinotecan crosses the BBB, making it relevant for the treatment of GBM patients. Third, a 582	  
phase II study found that 15% of recurrent GBM patients had a partial response to Irinotecan as a 583	  
single agent. One study suggests that combination of Bevacizumab  (10 mg/kg) with Irinotecan (either 584	  
340 mg/m2 or 125 mg/m2) results in increased six-month PFS from 42.6% with Bevacizumab alone to 585	  
50.3% with Bevacizumab plus Irinotecan [67]. A second phase II study with twenty-three grade IV 586	  
recurrent GBMs found that this combination induced thirteen partial responses [10]. Combination 587	  
therapy suggests an improvement over single agent alone as Bevacizumab, when given as a single 588	  
agent at 15 mg/kg every three weeks, resulted in a median OS of 6.5 months [97] while combination 589	  
treatment (Bevacizumab 10 mg/kg; Irinotecan either 340 mg/m2 or 125 mg/m2) resulted in a 40 week 590	  
(~10 month) OS [10].  However, some GBM tumors do not decrease in size, and these GBM patients 591	  
have a two and a half month median survival [97].  Thus, targeting tumor vasculature, whether by 592	  
single or combination therapy, has been challenging for glioblastomas.   593	  
To understand the mechanisms that promote Bevacizumab resistance, researchers analyzed tumors 594	  
from three GBM patients that initially responded but then relapsed [100]. Prior to treatment, the initial 595	  
tumor biopsies contained abnormal and increased vascular proliferation. After Bevacizumab treatment, 596	  
the tumors had almost no hyper-proliferative blood vessels, glomeroid tufts, or proliferating 597	  
endothelial cells. The relapses seemed counter-intuitive as the data suggested that the patients were 598	  
responding to the treatment. However, MRIs of the GBM patients indicated that the Bevacizumab-599	  
resistant tumors were highly infiltrative following treatment. IHC of the resistant tumors suggested 600	  
potential mechanisms for this increased invasiveness as increased hypoxia and levels of insulin 601	  
binding protein 2 and matrix metalloproteinase 2 were found.   602	  
Researchers began to explore the paradox of Bevacizumab-induced tumor invasiveness using 603	  
immunodeficient mice to recapitulate the observations in GBM patients [100].  Researchers 604	  
intracranially injected a non-invasive GBM cell line into mice, which were treated for four to six 605	  
weeks with Bevacizumab.  They observed that a subset of tumors became highly invasive in response 606	  
to the treatment and determined via IHC analysis that these tumors had decreased vascular 607	  
proliferation but increased expression of MMP2, consistent with the Bevacizumab-resistant human 608	  
GBM tumors [100].  To delineate the mechanism driving increased infiltration, one group 609	  
subcutaneously implanted a GBM cell line, U87, into the flanks of mice and treated them with 610	  
Bevacizumab every three days for 40 days, creating Bevacizumab-resistant tumors [101].  Tumor 611	  
samples were collected over the time course, allowing analysis of the molecular changes in these 612	  
tumors, which, by day 40, were resistant to Bevacizumab.  IHC of resistant tumors found that CD31 613	  
and CD34, well-established endothelial cell markers, were decreased, blood vessel density was 614	  
reduced, and the tumors expressed elevated levels of HIF1 alpha. This suggested that Bevacizumab 615	  
reduced the tumor vasculature but as a result, created a hypoxic environment. Microarray analysis 616	  
revealed that genes regulating glycolysis were up-regulated while genes regulating oxidative 617	  
respiration were down regulated in Bevacizumab-resistant versus sensitive tumors, suggesting that 618	  
Bevacizumab treatment induces a shift from mitochondrial respiration to glycolysis, a possible 619	  
mechanism of resistance [101, 102]. The microarrays also indicated that HIF targets were up-620	  
regulated, such as the glucose transporter Glut1, and key players in the TCA cycle, succinate 621	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dehydrogenase and fumarate, which also act as tumor suppressor genes, were down-regulated.  622	  
Researchers then proposed that drugs that inhibit glycolysis may increase the efficaciousness of 623	  
Bevacizumab as GBM cells are forced to used oxidative respiration [101, 102]. When mice were 624	  
treated with both Bevacizumab and dichloroacetate (DCA), a known inhibitor of glycolysis that can 625	  
cross the BBB, the combination treatment significantly decreased tumor growth versus either agent 626	  
alone [101]. Combination-treated tumors had decreased Ki67 staining, suggesting that the dual 627	  
treatment resulted in decreased proliferation that was cytostatic with no significant changes in necrosis 628	  
between single or double treated tumors. The reduced tumor growth observed in the combined therapy 629	  
may be due to Bevacizumab decreasing tumor vasculature, thereby creating a hostile, hypoxic 630	  
environment for the GBM cells, which is exacerbated by DCA.  In a small study, the combination of 631	  
DCA with the standard of care showed some tumor regressions [103]. This suggests that DCA may 632	  
have some efficacy when combined with the standard of care and perhaps may have increased efficacy 633	  
when used in combination with Bevacizumab.  634	  
The development of drugs that inhibit the formation of GBM vasculature, reduce tumor growth, and 635	  
extend the OS of patients is limited and now associated with a switch to invasion and metastasis. The 636	  
most promising of anti-angiogenic drug, Bevacizumab, has shown some success in reducing GBM 637	  
tumor burden and normalization of the vasculature; however, it is linked to increased tumor 638	  
invasiveness [100, 102]. In addition, GBM patients become less sensitive to the treatment over time. 639	  
This resistance could be due in part to the fact that the monoclonal antibody only targets one member, 640	  
VEGFA, of the five members of the VEGF family, allowing other VEGFs to compensate [10].  641	  
Resistance can also occur by activating other angiogenic pathways. For instance, EGFR, which is 642	  
amplified and over-expressed in GBM tumors, can contribute to angiogenesis as well as the well-643	  
studied NOTCH/Dll4 interaction and ANG/Tie pathway [10, 104-106].  Despite great progress, much 644	  
remains to be resolved in order to develop successful anti-angiogenesis therapies to extend the OS of 645	  
GBM patients. 646	  
5. Autophagy 647	  
Macroautophagy, referred to as autophagy here, is the process by which cells degrade and recycle 648	  
cellular content in response to stress or starvation providing the cell with a source of energy until 649	  
nutrients become available. During this process, a double-membrane cytosolic vesicle, known as the 650	  
autophagoasome, envelopes macromolecules and even whole organelles. Autophagosomes fuse with 651	  
lysosomes to form autolysosomes, resulting in the degradation of cellular contents. Autophagy occurs 652	  
in cells at a basal level and is required for homeostasis (as reviewed by [107-109]). In the context of 653	  
glioma cells, autophagy acts as a mechanism following chemotherapy treatment for both cell survival 654	  
[110-113] and cell death [114-116]. 655	  
5. 1 Therapy Induced Autophagy 656	  
TMZ induces autophagy in glioma cells as demonstrated by the increase in LC3-GFP-positive 657	  
vacuoles and levels of LC3B-II, as well as an accumulation of auto-fluorescent monodansylcadaverine 658	  
in authophagic vacuoles [110, 113, 117]. Earlier studies demonstrated that clinically relevant doses of 659	  
TMZ- induced autophagy without apoptosis [110]. These studies simultaneously showed that 660	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inhibition of autophagy through treatment with bafilomycin A, an inhibitor of vacuolar type H+-661	  
ATPase, led to induction of caspase-3 activation and subsequent apoptosis,; illustrating that autophagy 662	  
is one mechanism by which glioma cells can escape cell death. Knizhnik et al [113] showed that TMZ-663	  
induced autophagy occurs as a result of O6-MeG lesions that arise from TMZ treatment. Exogenous 664	  
expression of the repair enzyme MGMT inhibited induction of autophagy in these glioma cultures 665	  
while inhibition of MGMT led to an increase in autophagy. Disruption of the MSH2-MSH6 complex 666	  
or ATM kinase, via siRNA knockdown, abrogated autophagy, demonstrating that an intact MMR and 667	  
ATM kinase is required for autophagy induction. Time course studies following TMZ treatment 668	  
showed that autophagy is detected as much as two days before apoptosis in several glioma lines. 669	  
Inhibition of autophagy in these studies leads to not only an increase in apoptosis and, but allowed 670	  
apoptosis to occur at an earlier time point. Autophagy was also shown to precede and be required for 671	  
senescence, thus explaining how autophagy could contribute to cell survival following TMZ treatment.  672	  
Autophagy in gliomas has also been shown to be stimulated not only through cellular damage, as 673	  
seen with TMZ treatment, but also through various metabolic stresses, such as nutrient or growth 674	  
factor deprivation, providing the cell with a survival mechanism. Filippi-Chiela et al [118] focused 675	  
their work on the effects of combination treatment of TMZ with Resveratrol, a dietary polyphenol 676	  
known to inhibit proliferation.  Glioma cell treatment with Resveratrol and TMZ led to an increase in 677	  
autophagy. Autophagy here had no role in the cytotoxicity of the treatment but rather acted in this case 678	  
as a cytoprotectant mechanism.  Similarly, glioma cells treated with the EGFR tyrosine kinase 679	  
inhibitor, erlotinib (Tarceva®), underwent autophagy with reduced cell death. Co-treatment with the 680	  
autophagy inhibitor, chloroquine (CQ), and erlotinib increased cell death [119]. Therapy-resistant 681	  
PTEN-mutant gliomas fail to undergo significant cell death in response to PI3K and mTOR inhibitors;, 682	  
however, treatment with a dual PI3K-mTOR inhibitor, PI-103, led to an induction of autophagy [111, 683	  
120]. Apoptosis was increased by inhibiting autophagosome maturation, with bafilomycin A1, in 684	  
conjunction with PI-103 treatment. Interestingly, this increase in apoptosis was not achieved with 685	  
individual PI3K, Akt, or mTORC inhibitors, including rapamycin, in combination with bafilomycin 686	  
A1; the combined inhibition of autophagy, mTOR and PI3K was required for cell death. These 687	  
observations were extended using the PI3K-mTOR clinical inhibitors, NVP-BEZ235 (Novartis). Initial 688	  
in vivo studies evaluating the therapeutic efficacy of NVP-BEZ235 alone showed an increase in 689	  
survival of mice in an U87 intracranial model over vehicle-treated mice [121]. Another in vivo 690	  
xenograft model showed that NVP-BEZ235 or CQ alone slowed tumor progression but tumor 691	  
regression and increased apoptosis was only achieved when NVP-BEZ235 in combination with CQ 692	  
was administered. This further supports the need to inhibit autophagy to drive tumor cells towards cell 693	  
death and ultimately achieve tumor regression. 694	  
 Inhibiting autophagy in combination with other therapies is a promising approach to reduce tumor 695	  
cell survival following chemotherapy and is now being tested in the clinic. CQ continues to be 696	  
evaluated as a treatment for gliomas [122] with clinical data indicating an increase in survival in 697	  
patients in a phase II trial that added 150 mg daily dose of CQ as part of their adjuvant regimen 698	  
(http://clinicaltrials.gov/ct2/show/NCT00224978, [108]). A study by Sotelo et al [123] showed patients 699	  
in the CQ treatment arm had a median-survival of 24 months versus 11 months in the control group 700	  
with a secondary study by Bricero et al validating these results [124]. Another phase I/II active trial is 701	  
evaluating the effects of adding hydroxychloroquine to temozolomide and radiation in newly 702	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diagnosed glioblastoma patients (http://clinicaltrials.gov/ct2/show/NCT00486603, [108]). CQ is well 703	  
tolerated for long periods of time with doses as high as 500 mg daily, making it a promising drug to be 704	  
combined with the current standard of care [122]. However, further research is need into the safety of 705	  
this regimen. Autophagy helps maintain homeostasis in many of the body’s organs and inhibiting 706	  
autophagy may sensitize normal cells to chemotherapy [109]. Simultaneously, resistance to autophagy 707	  
inhibition may occur some tumors rendering this approach non-applicable [125]. 708	  
5.2 Radiosensitivity and Autophagy 709	  
Radiotherapy constitutes an important part of GBM treatment; however, obstacles remain in that 710	  
cells resistant to radiation contribute to tumor recurrence. Therefore, it is important to elucidate the 711	  
mechanisms responsible for differences in radiosensitivity of glioma cells. Autophagy is one of the 712	  
mechanisms implicated in the response of glioma tumor cells to radiation. Several studies have shown 713	  
that autophagy enhances radiosensitivity and leads to the induction of cell death [114, 115]. Radiation 714	  
alone or in combination with TMZ has been shown to activate autophagy in selectedhighly 715	  
radiosensitive glioma cultures that are highly radiosensitive. Knockdown of key components of the 716	  
autophagy pathway, Beclin-1 and Atg-5, inhibited autophagy, reducing sensitivity to radiation alone or 717	  
in combination with TMZ. Sensitization of glioma cultures to radiation was achieved after treatment 718	  
with rapamycin, a known inducer of autophagy [115]. Studies by Zhuang et al on glioma-initiating cell 719	  
lines observed similar results. CD133+ neurospheres showed increased autophagy when exposed to 720	  
rapamycin and radiation. In vivo treatment of mice with intracranial tumors with rapamycin and 721	  
radiation resulted in increased survival compared to radiation or rapamycin alone [114]. Similarly, 722	  
glioma cells treated with the dual PI3K-mTOR inhibitor, NVP-BEZ235, exhibited greater sensitivity to 723	  
IR as a result of the activation of autophagy [116].  724	  
In contrast, other studies have linked autophagy as a cytoprotective mechanism induced in response 725	  
to IR and thus, subsequent inhibition has been linked to increased radiosensitivity. Radiotherapy of 726	  
primary glioma stem-like cells with CQ alone or in combination with a PI3K/mTOR inhibitor 727	  
increased cell death [112]. In the context of NVP-BEZ235, it was shown that inhibition of NVP-728	  
BEZ235-induced autophagy with 3-methyladenine or CQ increased radiosensitivity. One explanation 729	  
proposed to explain the conflicting studies is that NVP-BEZ235 simultaneously induces autophagy 730	  
(decreasing radiosensitivity) and impairs DNA damage repair (increasing radiosensitivity) [126]. The 731	  
balance between autophagy and impairment of DNA damage repair may be a critical determinant of 732	  
radiosensitivity. 733	  
 It is important to note that radiosensitization by NVP-BEZ235 is dependent on the drug-734	  
irradiation schedule. Cells treated with NVP-BEZ235 prior to IR arrested in G1 and showed less DNA 735	  
damage as assessed by histone γH2AX expression. Interestingly, cells in this schedule regimen had less 736	  
DNA damage than irradiation only controls, potentially due to an induction of a survival mechanism 737	  
such as autophagy. In contrast, NVP-BEZ235 administration before, during, and after radiation 738	  
sensitized glioma cultures which was characterized by an increase in apoptosis, DNA damage, a 739	  
prolonged G2/M arrest [127]. 740	  
To summarize, the role of autophagy in resistance to therapy is unusually complex because 741	  
autophagy can enhance cell death or survival, often depending on the cell identity and the details of the 742	  
treatment. Additional laboratory studies and clinical trials are needed to determine whether autophagy 743	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can be manipulated to enhance cancer therapy.An on-going phase II clinical trial is evaluating the 744	  
effect of administering 200 mg hydroxychloroquine orally twice a day in combination to short course 745	  
radiation therapy versus radiotherapy alone (http://clinicaltrials.gov/show/NCT01602588, [112]). This 746	  
study will help address what, if any, is the clinical relevance of inhibiting autophagy. 747	  
6. Emerging Approaches to Therapies 748	  
6.1 Development of Novel TMZ-like Drugs 749	  
TMZ is a successful drug with oral administration, manageable side effects and enhanced survival 750	  
for patients with glioblastomas [6, 7, 13]. However, its most toxic product, O6-MeG, is readily 751	  
reversed by MGMT, and methylation of DNA at other sites is reversed by BER. A drug with less 752	  
readily repaired products would enhance therapy in the clinic. However, TMZ may reach brain tumors 753	  
and react with DNA more effectively than these new compounds. Fortunately, TMZ and related 754	  
compounds have been extensively studied, and this information will facilitate design of TMZ-like 755	  
drugs with increased anticancer activity and good pharmacokinetics. 756	  
Two approaches are currently being taken to development new TMZ derivatives that are resistant 757	  
to, or avoid, the two principal constraints on the ability of a tumor to respond to TMZ therapy, viz, 758	  
MGMT and MMR dependence.  One approach has been to adjust the imidazotetrazine 3-substiuent so 759	  
that the group transferred to DNA G-O6 sites is either not recognized or not repaired by MGMT.  A 760	  
range of neutral polar and charged G-O6 substituents resistant to cleavage by MGMT has been 761	  
characterized [128]. Several such substituents have been incorporated into experimental 762	  
imidazotetrazines 2, 3.  Other than the free carboxylic acid (2, R=H), these compounds have all been 763	  
shown active against GBM and colorectal cells lines that are resistant to TMZ, whether because of 764	  
proficient MGMT or having deficiency or mutation in the MMR components hMLH1 or hMSH6. 765	  
Onset of repair processes was slower than for TMZ and replication-independent (i.e. MMR-766	  
independent) DSBs were implicated in the cellular mechanism. The inactivity of the free carboxylic 767	  
acid is interesting as it indicates a prodrug role for the esters in facilitating cellular penetration of the 768	  
ionizable carboxylic functionality [129]. Carboxymethyl guanine is a known mutagenic metabolite, 769	  
resistant to MGMT repair but is a potential O6-MeG precursor that is generated from nitrosoglycine 770	  
that forms during amino acid digestion in the stomach [130, 131]. 771	  
 772	  
In the second approach a complete switch of chemical mechanism has been achieved with the dual 773	  
aims of avoiding MGMT and MMR dependence and making the drug more efficient than TMZ by 774	  
generating pharmacological activity from the major reaction site on DNA, GN7 (70% for TMZ), rather 775	  
than the minor (5%) G-O6 site.  This advance employs a neighboring group participation mechanism 776	  
to control the behavior of the released alkyldiazonium ions, Scheme 5. This serves the dual functions 777	  
of controlling reactivity, so giving the electrophile time to locate its reaction site on DNA, and 778	  
delivering an alternative form of damage to DNA. Since the response of tumors to TMZ is determined 779	  
by the interaction of DNA repair systems with modified DNA, altering the electrophile would 780	  
necessarily alter the profile of tumor responses. In these respects, the potential of the imidazotetrazines 781	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as acid-stable precursors of aziridinium ions was explored as these are reactive intermediates of proven 782	  
clinical utility, widely found in or generated by synthetic and natural product anti-tumor drugs, e.g., 783	  
nitrogen mustards. The bifunctional agent DP68 and its analogous monofunctional form DP86 are 784	  
currently under preclinical investigation. 785	  
 786	  
The aqueous chemistry of diazonium ions is beset by problems of competing hydrolysis, 787	  
elimination and re-arrangement reactions, which are reduced for aziridinium ions.  In a 13C labeling 788	  
study, DP86 was shown to be an efficient precursor of aziridinium ions (Scheme 5). At the stage of the 789	  
diazonium ion, there was 96% conversion to the aziridinium form with only 4 % direct hydrolysis. 790	  
Products of further reaction had the labeled atom scrambled so that it appeared equally at both 791	  
positions of the ethyl chain: confirming that they were entirely derived via the aziridinium route.  792	  
Highly effective control of the diazonium ions had been achieved – in sharp contrast to other agents 793	  
designed as precursors of aminoethyldiazonium ions [132]. 794	  
Scheme 5. Reaction of DP86 in phosphate buffer pD = 7.4.  * Sites of 13C labelling. 795	  
 796	  
The in vitro profiling of these compounds is very promising.  In screening against A2780 (MMR+, 797	  
MGMT+) and A278-cp70 (MMR–, MGMT+) cells in the presence and absence of PaTrin2 [36], 798	  
monofunctional compounds such as DP86 were as potent as mitozolomide (the more potent but 799	  
myelosuppressive 3-chloroethyl analogue of TMZ).  The bifunctional agents were significantly more 800	  
active than TMZ. MMR dependence was greatly reduced (from about 27-fold effect on IC50 for TMZ 801	  
to 2–5-fold) and MGMT dependence effectively null. NCI screening data showed that the new 802	  
compounds were not uniformly cytotoxic and confirmed the absence of correlation between activity 803	  
and MMR and MGMT. Moreover, matrix COMPARE analysis showed that the new agents are 804	  
pharmacologically distinct from standard agents that generate aziridinium or diazonium ions, that react 805	  
at G-N7 or G-O6, or crosslink DNA such as nitrogen mustards, nitrosoureas and cisplatin. The 806	  
chemosensitizing effect of these compounds is also independent of p53 [133]. DP68 has further been 807	  
shown to effectively crosslink DNA in cells [R.M. Phillips, personal communication] and the 808	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biochemical response to the crosslinks is mediated through the ATR/FANCD2 pathway [52]. This 809	  
finding is doubly significant as it shows that there is an escape pathway for healthy cells to survive 810	  
damage by DP68, and also that a tumor with deficiency or mutation in the ATR/FANCD2 pathway 811	  
(which includes BRCA1 and BRCA2) would be hypersensitive to this agent. 812	  
6.2 Drugs Directed Against Isocitrate Dehydrogenase 813	  
Using large-scale sequencing, several novel and exciting glioblastoma-associated mutations were 814	  
identified [134]. They found that 50-80% of low-grade gliomas carried mutations of isocitrate 815	  
dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2). Later studies showed that 5% of 816	  
primary glioblastomas and 60-90% of secondary glioblastomas express mutant IDH proteins [135, 817	  
136]. In addition, many acute myeloid leukemias bear IDH mutations. Although a variety of other 818	  
tumor types bear IDH mutations, the percentages of mutation-positive tumors are much less than for 819	  
glioblastoma and acute myeloid leukemia. Only one IDH gene copy is mutated, and either IDH1 or 820	  
IDH2, but not both, is mutated. These enzymes catalyze the oxidative decarboxylation of isocitrate, 821	  
producing α-ketogutarate (α-KG) and regenerating NADPH as part of the tricarboxylic (TCA) cycle. 822	  
IDH1 is present in the cytoplasm and peroxisomes; IDH2 is mitochondrial. For both enzymes, 823	  
arginines in the catalytic pocket (IDH1 R132 and IDH2 R140 or R172) were mutated. The uniqueness 824	  
of these mutations suggested a gain-of-function mutation, and a subsequent study demonstrated that 825	  
these mutated IDH enzymes reduced α-KG to an oncometabolite, 2-hydroxyglutarate (2-HG) [137]. 826	  
Overexpression of these mutated IDH enzymes induces histone and DNA hypermethylation and blocks 827	  
cellular differentiation. 828	  
Although 2-HG was only recently discovered, several exciting targets have been identified that 829	  
might drive cancer growth and progression [138]. One appealing model is that 2-HG, which 830	  
accumulates to high levels in cells with IDH mutations, competitively inhibits α-KG-dependent 831	  
enzymes. This competition is plausible since the structures of α-KG and 2-HG are quite similar. There 832	  
are approximately 70 known and predicted human α-KG-dependent dioxygenases. In particular, the 833	  
TET family of enzymes hydroxylates 5-MeG to generate 5-hydroxymethylcytosine, which is a step in 834	  
DNA demethylation. 2-HG may also inhibit histone demethylases, which are known to act as tumor 835	  
suppressors. Finally, 2-HG may inhibit the EglN family that hydroxylates proline residues on HIFα. 836	  
By inhibiting this reaction, 2-HG allows accumulation of HIFα and increases tumor cell responses to 837	  
hypoxia. These are all exciting cancer-relevant models, and undoubtedly additional targets will be 838	  
discovered. 839	  
A natural question is whether IDHs are targets for therapy. Although IDH is universally expressed, 840	  
the unique IDH mutations could be specifically targeted, lowering levels of 2-HG and hopefully 841	  
retarding tumor growth. This is particularly appealing for low-grade gliomas for which there are few 842	  
appealing treatment possibilities. In two recent studies, promising IDH inhibitors were described [139, 843	  
140]. Both the IDH1 and IDH2 inhibitors showed marked preferences for the cancer-mutated IDH 844	  
enzymes. Wang et al [139] inhibited the mutated IDH2 enzyme in leukemia cells, slowing cell 845	  
proliferation and inducing differentiation. Rohle et al [140] used the IDH1 inhibitor to slow 846	  
proliferation of glioblastoma cells, induce demethylation of histones and enhance astroglial 847	  
differentiation. These results have exciting applications for the clinic. For example, a mutated IDH 848	  
inhibitor with low toxicity might delay progression of low-grade to high-grade tumors. 849	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7. Conclusions 850	  
GBMs are chemotherapeutic resistant tumors with limited treatment options.  The current standard 851	  
of care enhances the OS of patients but does not cure or prevent recurrences. Understanding the 852	  
mechanisms that generate resistance is essential to developing more effective chemotherapies. Many 853	  
studies have demonstrated that DNA repair pathways, such as MGMT, BER and MMR, reverse 854	  
chemotherapy-induced damage and mediate resistance in gliomas. Inhibition of MGMT continues to 855	  
be the main therapeutic approach to overcome resistance in GBMs. CSCs contribute to tumor 856	  
recurrence as once therapy is completed the cells can re-populate the tumor. Furthermore, it has been 857	  
suggested that GBM CSCs can differentiate into GECs to provide the tumor with the vasculature 858	  
necessary to survive. In addition, autophagy may facilitate survival of some cells following 859	  
radiotherapy and chemotherapy making inhibition of autophagy a promising new target for therapy. 860	  
However, autophagy can induce cell death, demonstrating that a better understanding into what 861	  
dictates survival versus cell death roles of autophagy is still required. 862	  
Investigators are exploring a variety of novel approaches to improve GBM therapy. Currently, 863	  
medicinal chemists are synthesizing new imidazotetrazine analogues that hopefully will be more 864	  
effective than TMZ. The key to this approach is to circumvent DNA repair pathways with drugs that 865	  
form adducts that cannot be processed. Furthermore, inhibitors that specifically target mutated IDH 866	  
may provide physicians with a drug to slow or prevent the progression of low-grade tumors to GBMs 867	  
with few side effects. Elucidation of the mechanisms that promote resistance and recurrence may 868	  
provide novel targets that will improve the standard of care and overall survival. 869	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